Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gantenerumab - Roche

Next Previous
X
Search
Drug Profile

Gantenerumab - Roche

Alternative Names: R-1450; RG-1450; RO-4909832

Latest Information Update: 26 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer Chugai Pharmaceutical; Roche; Washington University School of Medicine
  • Class Antidementias; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 16 Jul 2023 Pooled efficacy and pharmacokinetics data from the phase III GRADUATE-I, GRADUATE-II, SCarlet RoAD and Marguerite RoAD trial in early Alzheimer's disease presented at Alzheimer's Association International Conference (AAIC-2023)
  • 22 Apr 2023 Pooled efficacy and safety data from pharmacokinetic phase I and phase II trials in Healthy volunteers at the 75th Annual Meeting of the American Academy of Neurology (AAN-2023)
  • 22 Apr 2023 Pooled efficacy data from the phase III GRADUATE-1 and GRADUATE-2 trial in early Alzheimer's disease presented at the 75th Annual Meeting of the American Academy of Neurology 2023 (AAN-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top